Drugs

LGM Pharma Solutions, LLC

FDA issued a warning letter to LGM Pharma Solutions, LLC (Boca Raton, FL, United States) on Nov 2, 2026, citing 21 CFR 211.192 and 21 CFR 211.100. Subject: CGMP, Finished Pharmaceuticals, Adulterated.

From the letter: “Your firm failed to adequately investigate out-of-specification (OOS) assay results obtained at multiple stability testing timepoints of both process validation and commercial batches for (b)(4) tablets.”

Boca Raton, FL, United StatesIssued Nov 2, 2026Posted Nov 17, 2026No close-out recorded

At a glance

What a reviewer notes before reading: findings, citations, the response deadline and what the letter warns of.

Violations
2 findings · 2 issue types
Response due
Fifteen (15) business days of receipt
FDA asks for
8 actions
Named as possible actions
Seizure, injunction
Issued by
Center for Drug Evaluation and Research
Published status
No close-out recorded

AI assisted findings

Model-assisted reading of each issue. Open one to see the FDA text it comes from, and check it against the full letter.

01Investigations & OOS · 21 CFR 211.192The firm failed to thoroughly investigate OOS assay results at multiple stability timepoints for process validation and commercial batches.
Your firm failed to adequately investigate out-of-specification (OOS) assay results obtained at multiple stability testing timepoints of both process validation and commercial batches for (b)(4) tablets.
02Production & process controls · 21 CFR 211.100(a)The firm failed to adequately validate the manufacturing processes for its tablets, including approving a process validation report despite a confirmed OOS failure.
Your firm failed to adequately validate the manufacturing processes for your (b)(4) tablets. Specifically, your process validation protocol required passing results for three batches of the (b)(4). During process performance qualification (PPQ), (b)(4) batch of (b)(4) failed to meet (b)(4) specification for one of the active ingredients, (b)(4).

Additional FDA passages

2 extracted findings

Selected FDA passages, not the complete letter.

01

Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).

02

Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).

What FDA requested

  • Provide a comprehensive independent assessment of laboratory practices, procedures, methods, equipment, documentation, and analyst competencies.
  • Provide a retrospective independent review of all invalidated OOS results for drug products in the U.S. market and within expiry.
  • Provide a comprehensive review and remediation plan for the OOS result investigation systems.
  • Provide a remediation plan for ongoing management oversight throughout the manufacturing lifecycle of all drug products.
  • Provide a detailed summary of the validation program approved at the time of manufacturing to support current batches in expiration.
  • Provide a timeline for performing appropriate process performance qualification for each marketed drug product.
  • Provide a risk assessment and follow-up actions for distributed drug products produced prior to process validation studies.
  • Notify the office before resuming manufacturing operations and provide a summary of remediations.

FDA Warning Letter

57 paragraphs · 5 sections

Text as published on FDA.gov, retrieved Nov 18, 2026. Layout added for reading; the wording is FDA’s. View on FDA.gov (opens in a new tab)

DatedNovember 2, 2026
Reference320-27-18
AddressedMr. Prasad Raje

1Introduction

5 paragraphs

This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) inspection of your facility and provides you an opportunity to address them. Promptly address any violations described herein without delay, including ensuring that appropriate resources are allocated to fully address them and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.

Violations were observed and documented during an inspection of your drug manufacturing facility, LGM Pharma Solutions, LLC, FDA Establishment Identifier (FEI) 3017140477 at 17802 Gillette Ave., Irvine, CA, from May 11 to May 18, 2026. This inspection was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.

This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).

Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).

We reviewed your June 9, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.

2Violations of the Federal Food, Drug, and Cosmetic Act

29 paragraphs

The following are violations identified during our inspection and review. As a reminder, this is not an all-inclusive list of violations at your facility.

1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).

Your firm failed to adequately investigate out-of-specification (OOS) assay results obtained at multiple stability testing timepoints of both process validation and commercial batches for (b)(4) tablets. For example, you attributed OOS assay results of process validation batches to variability of both your analytical method and the incoming raw material, (b)(4). Your investigations concluded that these OOS results had no impact on drug product quality because the process validation batches were not released for commercial distribution. However, your investigation of OOS assay results for commercial batches listed the same root causes that were identified for process validation batches. Despite knowing this information, you continued to release commercial batches after your process validation batches.

You did not perform comprehensive investigations and extend the investigations to identify true root causes. Despite failing results, you did not implement appropriate and effective corrective actions and preventive actions (CAPA).

In addition, you did not take appropriate market action at the time you obtained a confirmed (b)(4) OOS assay result from a retest of (b)(4) tablets. Your OOS investigation remained open without scientific justification, and you delayed acknowledging your drug product failure’s impact on drugs that remained in distribution.

In your response, you state that inherent variability of the (b)(4) step of the analytical method may have contributed to OOS results.

Your response is inadequate because you did not provide data to support your claim of method variability. Your method validation should account for any inherent variability in drug product testing. You are responsible for ensuring that your method is suitable for its intended use. In addition, you did not provide a risk assessment of the quality impact of the OOS results on several batches of (b)(4) tablets that you manufactured and remain in expiration in the U.S. market. Furthermore, your OOS investigations were not extended to include an evaluation of your manufacturing process.

It is essential to conduct thorough well documented, and scientifically sound investigations to identify root causes of OOS results, evaluate all potentially affected batches, and implement timely and effective CAPA plans. Whenever an investigation lacks conclusive evidence of laboratory error, a thorough investigation of potential manufacturing causes must be performed. For more information about handling failing, out-of-specification, out-of-trend, or other unexpected results and documentation of your investigations, see FDA’s guidance document Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production at https://www.fda.gov/media/158416/download.

In response to this letter, provide:

A comprehensive independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.

A retrospective, independent review of all invalidated OOS (including in-process and release/stability testing) results for drug products currently in the U.S. market and within expiry as of the date of this letter and a report summarizing the findings of the analysis, including the following for each OOS:o Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.o For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.o For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment/facilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation and any manufacturing operation improvements.

A comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include but not be limited to addressing the following:o Quality unit oversight of laboratory investigationso Identification of adverse laboratory control trendso Resolution of causes of laboratory variationo Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identifiedo Adequate scoping of each investigation and its CAPAo Revised OOS investigation procedures with these and other remediations

2. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).

Your firm failed to adequately validate the manufacturing processes for your (b)(4) tablets. Specifically, your process validation protocol required passing results for three batches of the (b)(4). During process performance qualification (PPQ), (b)(4) batch of (b)(4) failed to meet (b)(4) specification for one of the active ingredients, (b)(4). Your process validation report was approved despite the confirmed OOS (b)(4) failure which your report stated could not be adequately investigated because the remaining (b)(4) was consumed by tablet manufacturing. No justification or scientific rationale was included in your decision to conclude that your process validation was acceptable.

You also did not adequately assess in-process critical quality attributes (CQA) for the (b)(4) and (b)(4) tablets. For example, your process validation report stated there was variability for both particle size distribution of the (b)(4), and tablet thickness. In addition, your report stated that data results for these quality attributes were outside of your proposed ranges. You did not establish appropriate specifications for these attributes to ensure your finished drug products are manufactured reliably and reproducibly.

Furthermore, several process validation batches of (b)(4) tablets were reported with OOS assay results for (b)(4) at various stability timepoints. You concluded that these failures had no drug product quality impact or risk to patients because they were not distributed to the U.S. market. These multiple OOS results, obtained during PPQ for your (b)(4) tablets, demonstrate a process that is not in a state of control.

Appropriate controls and understanding of your manufacturing process are essential to ensuring a safe and effective drug product. We acknowledge that commercial batch (b)(4) of (b)(4) Tablets USP, (b)(4) ((b)(4)mg) that you manufactured was recalled for being (b)(4) for (b)(4).

We acknowledge that you have discontinued the manufacture and distribution of (b)(4) drug products, including (b)(4) tablets. This drug product has a narrow therapeutic range, adherence to the established specification of the label claim for the active ingredients is critical; it is especially important to prevent patients with (b)(4) from receiving insufficient or excessive doses.

In your response, you state that the majority of your investigations conclude the root cause for upward trending (b)(4) assay stability results for commercially distributed batches is likely due to the inherent variability of the (b)(4) step of the analytical method that you use. You also state that “…none of the commercial [batches] have a reportable result that lies outside the… specification[s] of the label [claim]….” You also indicate in your response that you could better understand the variability of your method and will evaluate and trend stability and release data for current batches.

Your response is inadequate. You did not provide trended drug product release and stability data for the (b)(4) tablets that remain in expiration and on the U.S. market. In addition, you have not fully and adequately evaluated your manufacturing process which includes the analytical method and establishing appropriate specifications for in-process CQA.

Your manufacturing process must be designed to consistently maintain a state of control so that it meets all of its chemical and microbiological attributes throughout its life cycle.

Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs.

Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch and inter-batch variation and determine whether an initial state of control has been established.

Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and drug product quality is necessary to ensure you maintain an ongoing state of control throughout the drug product lifecycle.

See FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https://www.fda.gov/regulatory-information/search-fda-guidancedocuments/process-validation-general-principles-and-practices.

In response to this letter, provide:

A remediation plan that better assures ongoing management oversight throughout the manufacturing lifecycle of all drug products. Provide a more data-driven and scientifically sound program that identifies sources of process variability, and assures that manufacturing operations meet appropriate parameters and quality standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, ensuring quality of input materials, determining the capability and reliability of each manufacturing process step and its controls, and vigilant ongoing monitoring of process performance and drug product quality.

A detailed summary of your validation program approved at the time of manufacturing of this drug product to support the current batches that remain in expiration in the U.S. market. Also, include an assessment of your validation program for all other drug products that you manufactured and distributed to the U.S. market ensuring a state of control throughout the drug product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing vigilant monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control. Also, describe your equipment and facility qualification program.

A timeline for performing appropriate process performance qualification for each of your marketed drug products. Also provide a risk assessment and any follow up actions to be taken for the distributed drug products produced prior to performing any process validation studies.

3Drug Production Ceased

3 paragraphs

We acknowledge your commitment to cease production of (b)(4) drug products at this facility.

If you plan to resume any manufacturing operations for (b)(4) drug products, notify this office before resuming your drug manufacturing operations. If you resume CGMP activities, you are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance.

In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all CAPA.

4CGMP Consultant Recommended

3 paragraphs

Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.

The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of all corrective action and preventive action, before you pursue resolution of your firm’s compliance status with FDA.

Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.

5Conclusion

6 paragraphs

You are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.

Unresolved violations may prevent other Federal agencies from awarding contracts. Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.

If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356c(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your drug products.

Response requested

Send your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter1. Identify your written response with FEI 3017140477 and ATTN: Christina Alemu-Cruickshank in the subject line of the email.

If you have information that you believe demonstrates that your drug products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.

FDA posts warning letters to www.FDA.gov.

Sincerely,/S/

Francis GodwinDirectorOffice of Manufacturing QualityOffice of ComplianceCenter for Drug Evaluation and ResearchU.S. Food and Drug Administration

________________

1 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans

Citations and trends

Each 21 CFR section, ISO 13485 clause and issue type in this letter, how often it appears across all letters, and its trend by the year FDA issued the letters. 2026 runs to Nov 10, 2026, compared with the same dates last year. Select a row or a bar to see those letters in Letters. As cited in this historical letter, not a statement of current requirements.

Regulations

Also cited: 21 CFR 210

Issue types

Investigations & OOSAI-assigned issue type202letters1finding here
49 letters issued this year vs 35 by the same date last year · +40%

Record details

Issuing center
Center for Drug Evaluation and Research
Issuing office
Center for Drug Evaluation and Research
Location
Boca Raton, FL, United States
Letter posted date
Nov 17, 2026
Letter issue date
Nov 2, 2026
Addressed to
Chief Executive Officer
Inspection dates
May 11, 2026 to May 18, 2026
Response window
Not verified in this snapshot. Consult the original letter.
Record length
2,471 words · 34 recorded redactions
Published status
No published close-out
FDA reference
320-27-18
Original letter
View on FDA.gov (opens in a new tab)
Dataset last checked
Nov 19, 2026 · How this is built

A response window is not a calculated due date. Source excerpts are selected passages. Finding interpretations and categories are model-assisted. Verify the original letter before relying on a finding.

See the pattern across 1,711 lettersFind letters like this →
Keep exploring

More drug letters

Recent records for the same product type. Your previous filters remain available when you return.

Keep exploring

Find letters like this →
For regulated teams

Put this kind of reading to
work on your own records.

Botable builds and runs a custom AI layer around the software you already use, so your team can do the job you hired them for.

Every letter by dateHow this database is built

FDA Warning Letter Alerts

Share this view

Send the same filters, search and view to a colleague.

You choose what to post or send. Sharing a link does not change access to this site.